



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Liu and Villarete

APPLICATION No.: 10/825,457

FILED: April 14, 2004

FOR: METHOD OF TREATMENT USING
INTERFERON-TAU

EXAMINER: Unassigned

ART UNIT: Unassigned

Information Disclosure Statement Within Three Months of
Application Filing or Before First Action – 37 C.F.R. § 1.97(b)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

1. Timing of Submission

This information disclosure is being filed within three months of the filing date of this application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever occurs last [37 C.F.R. § 1.97(b)]. The references listed on the enclosed Form PTO-1449 (modified) may be material to the examination of this application; the Examiner is requested to make them of record in the application.

2. Cited Information

- Copies of the following references are enclosed:
 - All cited references except U.S. patents and published applications
 - This application was filed after June 30, 2003, therefore copies of U.S. patents or published applications are not required.

3. Effect of Information Disclosure Statement (37 C.F.R. § 1.97(h))

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the cited information is, or is considered to be, material to patentability. In addition,

applicant does not admit that any enclosed item of information constitutes prior art to the subject invention and specifically reserves the right to demonstrate that any such reference is not prior art.

4. Fee Payment

No fees are believed due because this Information Disclosure Statement is being filed before the mailing date of the first Office Action.

However, should the Commissioner determine that fees are due in order for this Information Disclosure Statement to be considered, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 50-2207.

5. Patent Term Adjustment (37 C.F.R. § 1.704(d))

The undersigned states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this statement. 37 C.F.R. § 1.704(d).

Respectfully submitted,

Date: May 5, 2004

Judy M.
Judy M. Mohr
Registration No. 38,563

Correspondence Address:

Customer No. 22918
Perkins Coie LLP
P.O. Box 2168
Menlo Park, California 94026
(650) 838-4300

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Form PTO-1449 (Modified)
(Use several sheets if necessary)

MAY 05 2004
U.S. PATENT AND TRADEMARK OFFICE

COMPLETE IF KNOWN

Application Number	10/825,457
Confirmation Number	Unassigned
Filing Date	April 14, 2004
First Named Inventor	Liu and Villarete
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket No.	55600-8014.US02

Sheet

1

of

2

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent or Application		Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		NUMBER	Kind Code (if known)			
	1	5,705,363		Imakawa	01/06/98	
	2	5,906,816		Soos, et al.	05/25/99	
	3	5,958,402		Bazer, et al.	09/28/99	
	4	6,036,949		Richards, et al.	03/14/00	
	5	6,060,450		Soos, et al.	05/09/00	
	6	6,083,919		Johnson, et al.	07/04/00	
	7	2002/0013452	A1	Johnson, et al.	01/31/02	
	8	6,372,206		Soos, et al.	04/16/02	
	9	6,403,562		Johnson, et al.	06/11/02	
	10	2003/0012766	A1	Soos, et al.	01/16/03	
	11	2003/0049277	A1	Sokawa, et al.	03/13/03	
	12	2003/0130486	A1	Villarete, et al.	07/10/03	
	13	2003/0219405	A1	Sokawa, et al.	11/27/03	
	14	2004/0013643	A1	Mach	01/22/04	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent or Application		Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	NUMBER				
	15	PCT	WO 90/09806	Bazer, et al.	09/07/90		
	16	PCT	WO 94/10313	Bazer, et al.	05/11/94		
	17	PCT	WO 96/28183	Soos, et al.	09/19/96		
	18	PCT	WO 97/33607	Soos, et al.	09/18/97		
	19	PCT	WO 00/78266	Pontzer, et al.	12/28/00		

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published.	T
	20	Alexenko, A.P., et al., <i>Journal of Interferon and Cytokine Research</i> 17:769-779, (1997).	
	21	Bagaeva, L.V., et al., <i>Journal of Neuroimmunology</i> 137:109-116, (2003).	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).

[BY041200.091]

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
Form PTO-1449 (Modified)
(Use several sheets if necessary)

MAY 05 2004

JC:7

TRADEMARK OFFICE

Sheet	2	of	2	Attorney Docket No.
				55600-8014.US02

COMPLETE IF KNOWN

Application Number	10/825,457
Confirmation Number	Unassigned
Filing Date	April 14, 2004
First Named Inventor	Liu and Villarete
Group Art Unit	Unassigned
Examiner Name	Unassigned

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published.	T
	22	Brennan, F.R., et al., <i>J Med Microbiol</i> <u>41</u> :20-28, (1994).	
	23	Brod, S.A., et al., <i>Journal of Neuroimmunology</i> <u>58</u> :61-69, (1995).	
	24	Brod, S.A., et al., <i>Diabetologia</i> <u>41</u> :1227-1232, (1998).	
	25	Brod, S.A., <i>Journal of Interferon and Cytokine Research</i> <u>19</u> :841-852, (1999).	
	26	Carter, C.R.D., et al., <i>Clin Exp Immunol</i> <u>135</u> :233-239, (2004).	
	27	Filion, L.G., et al., <i>Clin Immunol</i> <u>106</u> :127-138, (2003).	
	28	Khan, O.A., et al., <i>Mult Scler</i> <u>4</u> (2):63-69, (1998).	
	29	Losy, J., et al., <i>Folia Neuropathol</i> <u>40</u> (4):173-175, (2002).	
	30	Makhlof, K., et al., <i>Journal of Neuroimmunology</i> <u>119</u> :145-149, (2001).	
	31	Moldovan, I.R., et al., <i>Journal of Neuroimmunology</i> <u>141</u> :132-140, (2003).	
	32	Mujtaba, M.G., et al., <i>Journal of Neuroimmunology</i> <u>75</u> :35-42, (1997).	
	33	Mujtaba, M.G., et al., <i>Cell Immunol</i> <u>186</u> (2):94-102, (1998).	
	34	Nakajima, A., et al., <i>Journal of Interferon and Cytokine Research</i> <u>22</u> :397-402, (2002).	
	35	Petereit, H.F., et al., <i>Journal of Neurological Sciences</i> <u>206</u> :209-214, (2003).	
	36	Pontzer, C.H., et al., <i>Biochem Biophys</i> <u>152</u> (2):801-807, (1988).	
	37	Pontzer, C.H., <i>Cancer Research</i> <u>51</u> :5304-5307, (1991).	
	38	Soos, J.M., et al., <i>Journal of Interferon and Cytokine Research</i> <u>15</u> :39-45, (1995).	
	39	Soos, J.M., et al., <i>Journal of Neuroimmunology</i> <u>75</u> :43-50, (1997).	
	40	Soos, J.M., et al., <i>The Journal of Immunology</i> <u>169</u> :2231-2235, (2002).	
	41	Tuohy, V.K., et al., <i>Journal of Neuroimmunology</i> <u>111</u> :55-63, (2000).	
	42	van Boxel-Dezaire, A.H.H., et al., <i>Ann Neurol</i> <u>45</u> :695-703, (1999).	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).